Skip to content

Study · Animal study (in vivo) · rat · 1992

3 results

Insulin-like growth factor-I and its N-terminal modified analogues induce marked gut growth in dexamethasone-treated rats.

Read LC, Tomas FM, Howarth GS, Martin AA, Edson KJ, Gillespie CM, Owens PC, Ballard FJ

The Journal of endocrinology1 Jun 1992Cited by 57 (Europe PMC)

PMID1613443 (opens in a new tab)DOI10.1677/joe.0.1330421 (opens in a new tab)PepBankPUB-01613443
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In dexamethasone-treated rats, the IGF-I analogues, including LR3IGF-I, had qualitatively similar gut effects to IGF-I but were consistently severalfold more potent.

    In plain wordsIn rats given dexamethasone, LR3IGF-I and another analogue had gut effects like IGF-I but were several times more potent.

    Peptide
    IGF-1 LR3
    Outcome
    IncreaseGut growth potency relative to IGF-I
    Study

    ratn: not reported in source

    150 g dexamethasone-treated rats
    Comparator
    IGF-I
    Outcome group
    Intestinal growth and absorption · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The IGF-I analogues had qualitatively similar effects to IGF-I, but were consistently severalfold more potent, providing evidence that IGF-binding proteins reduce the biological activity of exogenous IGF-I in the gut.
    1 context sentence
    Summary · context
    The effects of insulin-like growth factor-I (IGF-I) on the gut of 150 g dexamethasone-treated rats were compared with those of two analogues with reduced affinity for IGF-binding proteins, des(1-3)IGF-I and LR3IGF-I, an N-terminal-extended variant.

Studies that did not test the peptide alone2

In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking IGF-1 DES (des(1-3)IGF-I).

  1. 02AnimalNot a test of IGF-1 DES (des(1-3)IGF-I) aloneAnimal study (in vivo)Efficacy outcome

    In dexamethasone-treated rats, the two IGF-I analogues including des(1‑3)IGF-I had qualitatively similar gut effects to IGF-I.

    In plain wordsIn rats treated with dexamethasone, the two analogues including des(1‑3)IGF-I had qualitatively similar gut effects to IGF-I.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseQualitative gut growth effects of IGF-I analogues
    Study

    ratn: not reported in source

    dexamethasone-treated rats
    Outcome group
    Gastrointestinal protection · Gastrointestinal

    Source sentences

    Summary
    The IGF-I analogues had qualitatively similar effects to IGF-I, but were consistently severalfold more potent, providing evidence that IGF-binding proteins reduce the biological activity of exogenous IGF-I in the gut.
    1 context sentence
    Summary · context
    The effects of insulin-like growth factor-I (IGF-I) on the gut of 150 g dexamethasone-treated rats were compared with those of two analogues with reduced affinity for IGF-binding proteins, des(1-3)IGF-I and LR3IGF-I, an N-terminal-extended variant.

    In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).

  2. 03AnimalNot a test of IGF-1 DES (des(1-3)IGF-I) aloneAnimal study (in vivo)Efficacy outcome

    In dexamethasone-treated rats, the two analogues including des(1‑3)IGF-I were consistently severalfold more potent than IGF-I for gut effects.

    In plain wordsIn rats treated with dexamethasone, the two analogues including des(1‑3)IGF-I affected the gut more potently than IGF-I.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreasePotency of gut effects
    Study

    ratn: not reported in source

    dexamethasone-treated rats
    Comparator
    IGF-I
    Outcome group
    Gastrointestinal protection · Gastrointestinal

    Source sentences

    Summary
    The IGF-I analogues had qualitatively similar effects to IGF-I, but were consistently severalfold more potent, providing evidence that IGF-binding proteins reduce the biological activity of exogenous IGF-I in the gut.
    1 context sentence
    Summary · context
    The effects of insulin-like growth factor-I (IGF-I) on the gut of 150 g dexamethasone-treated rats were compared with those of two analogues with reduced affinity for IGF-binding proteins, des(1-3)IGF-I and LR3IGF-I, an N-terminal-extended variant.

    In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 3 to 4Current

    21 Oct 2026, 13:52 UTC

    The same notice was added 2 times, first on 21 Oct 2026, 12:50 UTC. The status did not change between them.

    Study data updated · source update from Europe PMC

  2. Version 2

    13 Oct 2026, 21:44 UTC

    Study results updated

  3. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.